The investigators aimed to confirm the efficacy and safety of transdermal penis enlargement for 24 weeks after CMDHA0101 injection in subjects who wanted penile enlargement in male patients with small-penis syndrome \*. \*Small-penis syndrome is the anxiety of thinking one's penis is too small - even though it isn't.
This study was designed as a 24-week, randomized, blinded, active control trial. If a subject signing a clinical trial agreement and satisfying the selection / exclusion criteria is enrolled in this clinical trial, he / she will receive the medical device for clinical testing at the baseline time, return to his / her home after the training . At 4 weeks, 12 weeks, and 24 weeks after the application of the medical device for clinical testing at baseline, the safety, penile girth, length, and satisfaction of the subject were evaluated. 24 weeks after application, the clinical trial sponsor (or trustee) retrieves the data necessary for the analysis of results, such as case records, for the purpose of validity and safety evaluation
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
68
Maximum injection dose : 22 ml
Maximum injection dose : 22 ml
Gangdong Sacred Heart Hospital, Hallym Univ
Seoul, Gangdong-gu/Gil-dong 445, South Korea
The difference in value from the basal value around the penis circumference after using the test device compared to the control device
Measured by value difference
Time frame: baseline, 24 weeks
The difference in value from the basal value around the penis circumference after using the test device compared to the control device
Measured by value difference
Time frame: baseline, 4 weeks, 12 weeks, 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.